Navigation Links
Biopharmaceutical Alliances: Forging Partnerships That Work
Date:4/30/2008

CHAPEL HILL, N.C., April 30 /PRNewswire/ -- Intense global competition and today's networked economy have been the driving force behind companies adopting Strategic Alliances as the strategy of the next century. A strategic alliance must be a win-win situation for it to be sustainable and mutually beneficial.

How to build a win-win alliance? Best Practices, LLC's study on Forging Partnerships That Work is a roadmap to successful alliance formation. This study evaluates the significance of 10 factors for driving success in the establishment and evolution of alliance.

Best Practices, LLC conducted the study with two main objectives: 1) To identify the factors that companies with most successful alliances consider important and 2) to explain why those factors are considered most important. This study further explores the winning strategies and practices of nine pharmaceutical and biotech companies that have engaged in successful strategic alliances.

Among the questions answered in this study (Please read more in the downloadable excerpt):

-- What are the decisions that need to be made when beginning the

partnering process?

-- How can a partnership be used most strategically?

-- What do you ask for in a licensing/co-promotion deal?

Download a complimentary report summary of "Profitable Partnerships: Developing Excellence in Alliances" at http://www3.best-in-class.com/rr938.htm .

If you have questions about this report or would like to speak to us about how our research can benefit your current initiatives in your company, please contact Cameron Tew, Manager of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic perf
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
3. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
4. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
5. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
6. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
7. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
8. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
9. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...land,November24/PRNewswire-FirstCall/--deCODE,gene...fallofits,"firstday"motionsbytheU.S.BankruptcyCour...eCODElastweekfiledavoluntarypetitionfor,reliefunde...ankruptcyCourt. , TheordersissuedbytheBankrup...nessduringtheChapter11proceedings.Inparticular,the...
(Date:11/24/2009)...24/PRNewswire-Asia/--ShanghaiBiolaxyannouncedthe,C...rovedthe,investigationalnewdrugapplication(IND)for...formulationtotreatdiabetes.ThisIND,approvalallowsB..., Diabetesisadisordercharacteristicofhighbloodgluc...tenresultinseveremicro-and,macro-vasculardiseases,...
(Date:11/24/2009)...cyendpointhasbeenmetforpatientswithadvanced-stage,...v.24/PRNewswire-FirstCall/-AEternaZentarisInc.(NAS...ceuticalcompanyfocusedonendocrinetherapyandoncolog...dywithitstargetedcytotoxicpeptideconjugate,AEZS-10...tendometrialcancer.Inapersonalizedhealthcareapproa...
(Date:11/24/2009)...24,2009/PRNewswire-FirstCall/--ArenaPharmaceutical...yisscheduledtopresentatthePiperJaffray21stAnnualHe...rnTime(8:30a.m.PacificTime)attheNewYorkPalaceHotel...xecutiveOfficer,isscheduledtoprovideanoverviewofth...ryprograms. ,, Aliveaudiowebcastofthepresentati...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
... Separate Study Also Show Minimal Effect on Heart ...Patients, VIENNA, Austria, Oct. 17 New data show...ng developed by Organon -- is effective,in treatin...isorder. These,results, from two Phase III clinica...ropean College of Neuropsychopharmacology (ECNP) C...
...st time theoretical modeling has provided a glimps... to trap charges, something which may affect the p... revealed in a paper published on the 12th October...London Centre for Nanotechnology and SEMATECH, a c...uest for miniaturization, transistors and all thei...
..., Oct. 16 NxStage Medical,Inc. (Nasdaq: NXTM ), ...ucts, announced plans to release its financial res...r 2, 2007 before the opening of the,financial mark...10:00 a.m. Eastern Time on,November 2, 2007 to dis...listen to the conference call, please dial 800.638...
Other Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6Novel gate dielectric materials: perfection is not enough 2NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2
(Date:11/23/2009)...research suggests that a common oral bacterium may...t by Nichols et al, "Unique Lipids from a Common H...ds Capable of Enhancing Autoimmunity," appears in ...f Pathology . , Multiple sclerosis (MS), a disea...pinal cord, affects nearly 1 in 700 people in the ...
(Date:11/23/2009)...swine vaccine available for the H1N1 virus has bee... virus. The vaccination marks the first time vacci...e pandemic flu., Iowa State University,s Hank Ha...accine this summer and has been shipping preventiv...inois for several weeks., The latest vaccines we...
(Date:11/23/2009)..., 2009 -- A USDOE and USDA study concluded that 50...d cropland pasture could be converted from current... as switchgrass, from which biomass could be harve...viable production of a perennial grass monoculture...removed annually is expected to require nitrogen f...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 1How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 2How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 3Misuse of Pain Medication Draws Heightened Concerns 54870 1Misuse of Pain Medication Draws Heightened Concerns 54870 2Misuse of Pain Medication Draws Heightened Concerns 54870 3Misuse of Pain Medication Draws Heightened Concerns 54870 4Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration 54866 1Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration 54866 2
...ch sun ?for plants as well as people ?can be harmf... equivalent of "lobster tans," plants have develop... photoprotection, which acts like sunscreen to war...olecules called carotenoids participate in this pr...n, how does this work?" said Iris Visoly-Fisher, a...
...e first time, researchers have developed a way to ...in in enough quantity to learn how it works. , Der...s of a New Zealand cave, the chemical tricks certa... cells untouched. , "In 2000, scientists in Japan...mendous potential as a prototype anticancer agent,...
...g a whole new interface between nanotechnology and...ve used slender silicon nanowires to detect, stimu...d dendrites of live mammalian neurons. , Harvard ... this marriage of nanowires and neurons this week ... artificial synapses between nanoelectronic device...
Other Biology News:How plants avoid feeling the burn 2How plants avoid feeling the burn 3How plants avoid feeling the burn 4New lab technique churns out fungus' potential cancer fighter 2Nanowire arrays can detect signals along individual neurons 2
Bsg I from New England Biolabs
Rabbit Anti-CUGBP2 Monoclonal Antibody, Unconjugated, Clone PADZMD.495 from Invitrogen
GIBCO Geneticin Selective Antibiotic liquid from Invitrogen
LB Broth Base powder (Lennox L Broth Base) from Invitrogen
Biology Products: